OM Pharma is set to present what it calls the largest multi-country real-world evidence study to date on Broncho-Vaxom (OM-85), spotlighting new data from its REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) 2026 Congress.

 

The company will unveil preliminary findings showing that Broncho-Vaxom was associated with a 28–38% reduction in respiratory tract infection rates at 12 months and a 29–41% reduction at 24 months, compared with the year before treatment initiation. The effect was consistent across patient groups, including different age ranges and infection histories.

 

The study evaluated a vast real-world cohort of 15,794 patients across China, Italy, and Belgium, spanning children as young as one year through to older adults, and including patients with comorbid conditions such as asthma, COPD, chronic bronchitis, and allergic rhinitis.

 

“The REACH real-world evidence study shows that Broncho-Vaxom can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. 

 

“Recurrency of respiratory infections is an important medical issue with severe impacts for patients. This extensive evidence in a real world setting strongly reinforces existing clinical data and should give physicians greater confidence that they have the possibility to address RTI recurrence, relieving patient burden.”

 

REACH is positioned as the first and largest multi-country real-world evidence study of its kind for Broncho-Vaxom, drawing on routinely collected healthcare data rather than controlled trial settings. The study is designed to reflect everyday clinical practice and includes patients with a wide range of underlying conditions.

 

For clinicians, the findings land squarely in the context of persistent global concern over recurrent respiratory tract infections, which are a major driver of healthcare visits, lost productivity, and antibiotic prescribing. Antibiotic overuse remains a key contributor to antimicrobial resistance, adding further weight to preventive approaches.

 

“For individuals living with recurrent respiratory infections, prevention is not just a clinical objective-it is key to reducing their overall disease burden. This study provides valuable real-world evidence demonstrating how preventive strategies can meaningfully lower infection rates. 

 

"Patients and families need solutions that enable healthier, more active lives, and research like this helps advance more informed, patient-centred care,” said Vildana Mujkić, Board Member and Eastern European Alliance Leader, Global Allergy & Airways Patient Platform (GAAPP).

 

The results also align with EAACI 2026’s theme, “Vision Zero: A Future Free from Allergy and Asthma Burden,” as respiratory infections are known triggers for asthma exacerbations and chronic airway inflammation.

 

A second primary endpoint—comparing matched untreated cohorts within real-world datasets—is still under analysis and is expected later this year.